Evaluation of Clinical, Pathological, and Treatment Effects on Prognosis in Non-Metastatic Esophagus Squamous Cell Carcinoma
DOI:
https://doi.org/10.58600/eurjther2917Keywords:
American Joint Committee on Cancer, Eastern Cooperative Oncology Group, Non-metastatic Esophageal Cancer, Response Evaluation Criteria In Solid Tumors, Squamous cell carcinomaAbstract
Objective: This study analyzed demographic, clinical, and pathological features, treatment responses, and survival outcomes in non-metastatic esophageal SCC patients.
Methods: A retrospective review of 74 patients was conducted. Performance status was assessed using ECOG, treatment response via RECIST 1.1, and staging via AJCC 7th edition TNM.
Results: The male-to-female ratio was 0.95, with a mean age of 50.6. Tumors were mainly distal (58%), and most patients (68.7%) presented at stage 2 (25%) or 3 (43.7%). Surgery was performed in 64.9% (47.3% surgery only, 35.1% CRT only, 17.6% CRT + surgery). Median overall and disease-free survival were 38 and 24 months, respectively. Female gender, middle/lower tumor location, fewer metastatic lymph nodes, and CRT + surgery correlated with better survival (p < 0.05).
Conclusion: Surgery was the most common treatment, but CRT + surgery yielded superior survival. Local recurrence was more frequent than distant metastasis. A combined approach is crucial for optimal outcomes.
References
[1] Oshima K, Tsushima T, Ito Y, Kato K (2024) Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma. Jpn J Clin Oncol. 54:395-402. https://doi.org/10.1093/jjco/hyae005
[2] Türkay D, Vural Ç, Sayan M, Gürbüz Y (2016) Detection of human papillomavirus in esophageal and gastroesophageal junction tumors: A retrospective study by real-time poly-merase chain reaction in an instutional experience from Turkey and review of literature. Pathol Res Pract. 212:77-82. https://doi.org/10.1016/j.prp.2015.10.007
[3] Qu HT, Li Q, Hao L, Ni YJ, Luan WY, Yang Z, Chen XD, Zhang TT, Miao YD, Zhang F. (2024) Esophageal cancer screening, early detection and treatment: Current insights and future directions. World J Gastrointest Oncol. 16:1180-1191. https://doi.org/10.4251/wjgo.v16.i4.1180
[4] Qi JH, Huang SL, Jin SZ (2024) Novel milestones for early esophageal carcinoma: From bench to bed. World J Gastrointest Oncol. 16:1104-1118. https://doi.org/10.4251/wjgo.v16.i4.1104
[5] Zhu LH, Yao J, Wu T, Wang Y, Wang CW, Xue CQ, Wu LG, Fan XW, Wu CY. (2020) Risk of Recurrence and Metastasis for Patients with T1N0M0 Esophageal Carcinoma Who Achieve Completed Resec-tion via Endoscopic Submucosal Resection: Evidence for the Appropriateness of the Watch and Wait Follow-Up Strategy. Cancer Manag Res. 12:2427-2435. https://doi.org/10.2147/cmar.S227959
[6] Liu J, Wei Z, Zhang J, Hu W, Ma Z, Liu Q (2016) Which factors are associated with ex-tremely short-term survival after surgery in patients with esophageal squamous cell carcino-ma? Asia Pac J Clin Oncol. 12:308-313. https://doi.org/10.1111/ajco.12503
[7] Uchinami Y, Myojin M, Takahashi H, Harada K, Shimizu S, Hosokawa M (2016) Prognos-tic factors in clinical T1N0M0 thoracic esophageal squamous cell carcinoma invading the muscularis mucosa or submucosa. Radiat Oncol. 11:84. https://doi.org/10.1186/s13014-016-0660-4
[8] Yang H, Chen Y, Huang X, Gu Y, Chen Z, Mao W (2024) Bioinformatics Analysis Reveals a Novel Prognostic Model for Esophageal Squamous Cell Carcinoma. Int J Med Sci. 21:1213-1226. https://doi.org/10.7150/ijms.93423
[9] Liu M, Yang W, Guo C, Liu Z, Li F, Liu A, Yang H, Shen L, Wu Q, Duan L, Wang H, Tian H, Shi C, Pan Y, Liu Y, Liu F, Weiss NS, Cai H, He Z, Ke Y. (2024) Effectiveness of Endoscopic Screen-ing on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screen-ing for Esophageal Cancer in China (ESECC) Randomized Trial. J Clin Oncol. 42:1655-1664. https://doi.org/10.1200/jco.23.01284
[10] Arnold M, Soerjomataram I, Ferlay J, Forman D (2015) Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 64:381-387. https://doi.org/10.1136/gutjnl-2014-308124
[11] Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, Gerger A, Benhaim L, Paez D, Wakatsuki T, Loupakis F, El-Khoueiry R, Zhang W, Lenz HJ. (2012) Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol. 30:2265-2272. https://doi.org/10.1200/jco.2011.38.8751
[12] Chen J, Zhu J, Pan J, Zhu K, Zheng X, Chen M, Wang J, Liao Z. (2010) Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus. Ann Thorac Surg. 90:435-442. https://doi.org/10.1016/j.athoracsur.2010.04.002
[13] Freedman ND, Abnet CC, Caporaso NE, Fraumeni JF Jr, Murphy G, Hartge P, Hollenbeck AR, Park Y, Shiels MS, Silverman DT. (2016) Impact of changing US cigarette smoking patterns on incident cancer: risks of 20 smok-ing-related cancers among the women and men of the NIH-AARP cohort. Int J Epidemiol. 45:846-856. https://doi.org/10.1093/ije/dyv175
[14] Fahey PP, Page A, Stone G, Astell-Burt T (2020) Augmenting cancer registry data with health survey data with no cases in common: the relationship between pre-diagnosis health behaviour and post-diagnosis survival in oesophageal cancer. BMC Cancer. 20:496. https://doi.org/10.1186/s12885-020-06990-3
[15] Schuring N, van Berge Henegouwen MI, Gisbertz SS (2024) History and evidence for state of the art of lymphadenectomy in esophageal cancer surgery. Dis Esophagus. 37:4;doad065. https://doi.org/10.1093/dote/doad065
[16] Wu J, Chen QX (2016) Prognostic and predictive significance of tumor length in patients with esophageal squamous cell carcinoma undergoing radical resection. BMC Cancer. 16:394. https://doi.org/10.1186/s12885-016-2417-8
[17] Situ D, Wei W, Lin P, Long H, Zhang L, Fu J, Rong T, Ma G. (2013) Do tumor grade and location affect survival in esophageal squamous cell carcinoma? Survival analysis of 302 cases of pT3N0M0 esophageal squamous cell carcinoma. Ann Surg Oncol. 20:580-585. https://doi.org/10.1245/s10434-012-2656-0
[18] Wang Y, Wang L, Yang Q, Li J, Qi Z, He M, Yao J, Qiao X. (2015) Factors on prognosis in patients of stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagecto-my. J Cancer Res Ther. 11 Suppl 1:C16-23. https://doi.org/10.4103/0973-1482.163833
[19] Bouvier AM, Binquet C, Gagnaire A, Jouve JL, Faivre J, Bedenne L (2006) Management and prognosis of esophageal cancers: has progress been made? Eur J Cancer. 42:228-233. https://doi.org/10.1016/j.ejca.2005.08.038
[20] Kim DE, Kim UJ, Choi WY, Kim MY, Kim SH, Kim MJ, Shim HJ, Hwang JE, Bae WK, Chung IJ, Nam TK, Na KJ, Cho SH. (2013) Clinical prognostic fac-tors for locally advanced esophageal squamous carcinoma treated after definitive chemoradi-otherapy. Cancer Res Treat. 45:276-284. https://doi.org/10.4143/crt.2013.45.4.276
[21] Fakhrian K, Heilmann J, Schuster T, Thamm R, Reuschel W, Molls M, Geinitz H. (2012) Prima-ry radiotherapy with or without chemotherapy in non-metastatic esophageal squamous cell carcinoma: a retrospective study. Dis Esophagus. 25:256-262. https://doi.org/10.1111/j.1442-2050.2011.01244.x
[22] Ordu AD, Nieder C, Geinitz H, Kup PG, Deymann LF, Scherer V, Combs SE, Fakhrian K. (2015) Ra-dio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus: long-term outcome. Strahlenther Oncol. 191:153-160. https://doi.org/10.1007/s00066-014-0779-x
[23] Chen WH, Huang YL, Chao YK, Yeh CJ, Chang HK, Tseng CK, Liu YH. (2015) Prognostic significance of lymphovascular invasion in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol. 22:338-343. https://doi.org/10.1245/s10434-014-3881-5
[24] Ning ZH, Zhao W, Li XD, Chen LJ, Xu B, Gu WD, Shao YJ, Xu Y, Huang J, Pei HL, Jiang JT. (2015) The status of perineural in-vasion predicts the outcomes of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 8:6881-6890
[25] Chen JW, Xie JD, Ling YH, Li P, Yan SM, Xi SY, Luo RZ, Yun JP, Xie D, Cai MY. (2014) The prognostic effect of peri-neural invasion in esophageal squamous cell carcinoma. BMC Cancer. 14:313. https://doi.org/10.1186/1471-2407-14-313
[26] Ma MQ, Yu ZT, Tang P, Jiang HJ, Zhao XJ, Zhang JG, Qu DW, Jin QW, Zhang XZ. (2015) Is tumor length a prog-nostic indicator for esophageal squamous cell carcinoma? A single larger study among Chi-nese patients. Int J Clin Exp Pathol. 8:5008-5016
[27] Bollschweiler E, Baldus SE, Schröder W, Schneider PM, Hölscher AH (2006) Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol. 94:355-363. https://doi.org/10.1002/jso.20569
[28] Wijnhoven BP, Tran KT, Esterman A, Watson DI, Tilanus HW (2007) An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg. 245:717-725. https://doi.org/10.1097/01.sla.0000251703.35919.02
[29] Xu Y, Yu X, Chen Q, Mao W (2012) Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? World J Surg Oncol .10:173. https://doi.org/10.1186/1477-7819-10-173
[30] Stahl M, Budach W, Meyer HJ, Cervantes A (2010) Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21 Suppl 5:v46-49. https://doi.org/10.1093/annonc/mdq163
[31] Matsuda S, Tsubosa Y,Sato H, Takebayashi K, Kawamorita K, Mori K, Niihara M, Tsushima T, Yokota T, Onozawa Y, Yasui H, Takeuchi H,Kitagawa Y. (2017) Com-parison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma. Dis Esophagus. 30:1-8. https://doi.org/10.1111/dote.12473
[32] Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V; Australasian Gastro-Intestinal Trials Group. (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesoph-ageal carcinoma: an updated meta-analysis. Lancet oncol. 12:681-692
[33] Zagouri F, Liakou P, Bartsch R, Peccatori FA, Tsigginou A, Dimitrakakis C, Zografos GC, Dimopoulos MA, Azim HA Jr. (2015) Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal. Breast .24:513-523. https://doi.org/10.1016/j.breast.2015.02.031
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Hatice Zeynep Dikici, Nuriye Özdemir, Selma Özkan Karaahmetoğlu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
